Calcitrene (calcipotriene topical) Disease Interactions
There is 1 disease interaction with Calcitrene (calcipotriene topical):
Calcipotriene Topical (Includes Calcitrene) ↔ Hypercalcemia
Severe Potential Hazard, High plausibility
Applies to: Hypercalcemia, Poisoning by Vitamins
The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcipotriene is a synthetic vitamin D3 analog. Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment. Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine. Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene. If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored. Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.
- Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot C, Bazex JA, Jurgensen HJ "Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle- controlled study." J Am Acad Dermatol 27 (1992): 983-8
- Murdoch D, Clissold SP "Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris." Drugs 43 (1992): 415-29
- "Product Information. Dovonex (calcipotriene)." Westwood Squibb Pharmaceutical Corporation, Eatontown, NJ.
- Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE "Urine calcium excretion during treatment of psoriasis with topical calcipotriol." Br J Dermatol 129 (1993): 411-4
- Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE "High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris." Br J Dermatol 129 (1993): 74-6
- Hardman KA, Heath DA, Nelson HM "Hypercalcaemia associated with calcipotriol (Dovonex) treatment." BMJ 306 (1993): 896
- Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P "Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double- blind, placebo-controlled study." Acta Derm Venereol 73 (1993): 300-4
- Dwyer C, Chapman RS "Calcipotriol and hypercalcaemia." Lancet 338 (1991): 764-5
Calcitrene (calcipotriene topical) drug Interactions
There are 136 drug interactions with Calcitrene (calcipotriene topical)
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.